liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
Linköping University, Department of Medical and Health Sciences, Division of Health Care Analysis. Linköping University, Faculty of Medicine and Health Sciences. Linköping University, Center for Medical Image Science and Visualization (CMIV). PAREXEL Int, Sweden.
PAREXEL Int, India.
AstraZeneca, Sweden.
AstraZeneca, Sweden.
Show others and affiliations
2016 (English)In: PharmacoEconomics (Auckland), ISSN 1170-7690, E-ISSN 1179-2027, Vol. 34, no 6, 569-585 p.Article, review/survey (Refereed) PublishedText
Abstract [en]

Critiques of cost-effectiveness modelling in type 1 diabetes mellitus (T1DM) are scarce and are often undertaken in combination with type 2 diabetes mellitus (T2DM) models. However, T1DM is a separate disease, and it is therefore important to appraise modelling methods in T1DM. This review identified published economic models in T1DM and provided an overview of the characteristics and capabilities of available models, thus enabling a discussion of best-practice modelling approaches in T1DM. A systematic review of Embase(A (R)), MEDLINEA (R), MEDLINEA (R) In-Process, and NHS EED was conducted to identify available models in T1DM. Key conferences and health technology assessment (HTA) websites were also reviewed. The characteristics of each model (e.g. model structure, simulation method, handling of uncertainty, incorporation of treatment effect, data for risk equations, and validation procedures, based on information in the primary publication) were extracted, with a focus on model capabilities. We identified 13 unique models. Overall, the included studies varied greatly in scope as well as in the quality and quantity of information reported, but six of the models (Archimedes, CDM [Core Diabetes Model], CRC DES [Cardiff Research Consortium Discrete Event Simulation], DCCT [Diabetes Control and Complications Trial], Sheffield, and EAGLE [Economic Assessment of Glycaemic control and Long-term Effects of diabetes]) were the most rigorous and thoroughly reported. Most models were Markov based, and cohort and microsimulation methods were equally common. All of the more comprehensive models employed microsimulation methods. Model structure varied widely, with the more holistic models providing a comprehensive approach to microvascular and macrovascular events, as well as including adverse events. The majority of studies reported a lifetime horizon, used a payer perspective, and had the capability for sensitivity analysis. Several models have been developed that provide useful insight into T1DM modelling. Based on a review of the models identified in this study, we identified a set of best in class methods for the different technical aspects of T1DM modelling.

Place, publisher, year, edition, pages
ADIS INT LTD , 2016. Vol. 34, no 6, 569-585 p.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:liu:diva-129148DOI: 10.1007/s40273-015-0374-8ISI: 000376104800004PubMedID: 26792792OAI: oai:DiVA.org:liu-129148DiVA: diva2:936060
Note

Funding Agencies|AstraZeneca

Available from: 2016-06-13 Created: 2016-06-13 Last updated: 2016-06-13

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Henriksson, Martin
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health SciencesCenter for Medical Image Science and Visualization (CMIV)
In the same journal
PharmacoEconomics (Auckland)
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 16 hits
ReferencesLink to record
Permanent link

Direct link